Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NSCLC × dacomitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 7 Brain Neoplasms 3 Recurrence 2 Neoplasm Metastasis 2 Head and Neck Neoplasms 2 Glioblastoma 2 Carcinoma, Squamous Cell 2 Squamous Cell Carcinoma of Head and Neck 1 Rare Tumor 1 Penile Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 NSCLC 1 Lung Neoplasms 1 Carcinoma 1 Advanced Gastric Cancer 1

Interventions

osimertinib 5 Carboplatin 5 Drug Therapy 4 tislelizumab 3 anlotinib 3 aflutinib 3 Radiotherapy 3 Pemetrexed 3 toripalimab 2 pembrolizumab 2 apatinib 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Radiosurgery 2 Paclitaxel 2 HM781-36B 2 Cisplatin 2 Chemotherapy, Adjuvant 2 Chemoradiotherapy 2 trilaciclib 1 surufatinib 1 sintilimab 1 rezivertinib 1 lenvatinib 1 icotinib 1 envafolimab 1 dacomitinib 1 cemiplimab 1 camrelizumab 1 brigatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04811001 2023-02-21

CAPLAND

Fondazione Ricerca Traslazionale

Phase 2 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡